Article Details

ImmunoMet Therapeutics Granted Fast Track Designation by US FDA for IM156 in Idiopathic ...

Retrieved on: 2021-05-03 18:00:00

Tags for this article:

Click the tags to see associated articles and topics

ImmunoMet Therapeutics Granted Fast Track Designation by US FDA for IM156 in Idiopathic .... View article details on hiswai:

Excerpt

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, ...

Article found on: www.valdostadailytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo